

Drug Monograph

Drug Name: **ArmonAir® Digihaler™ (fluticasone propionate) inhalation powder**
 Drug Class: **Inhaled Corticosteroids (ICS)**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: ArmonAir Digihaler is available as a multidose dry powder inhaler (MDPI) that delivers 55 mcg, 113 mcg, or 232 mcg of fluticasone propionate. This product contains a built-in electronic module.

Manufacturer: Distributed by: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054.

Indications: Maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older

Costs: \$239 per inhaler Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Megan Fast, PharmD.
 Date: October 23, 2020